活動性乾癬性関節炎患者におけるウパダシチニブの有効性と安全性: ２つのフェーズ３試験結果
Arthritis Res Ther. 2023;25(1):56 doi 10.1186/s13075-023-03027-5
Evidence from two phase 3 RCTs showed that patients with PsA and axial involvement had greater responses when treated with a once-daily oral dose of 15 mg upadacitinib versus placebo, and a similar or greater response versus adalimumab. Safety results were comparable between patients with or without axial involvement.